ArticleClinical therapeutics2018
Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009-2015.
Article in Clinical therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- The validity of ICD-based codes to identify pediatric cases of congenital cytomegalovirus.Current medical research and opinion · 2025Article
- Cranial Ultrasound Findings in Infants With Congenital Cytomegalovirus Infection in a Universal Newborn Screening Study in Minnesota.Journal of the Pediatric Infectious Diseases Society · 2024Article
- Autism Spectrum Disorder Diagnoses and Congenital Cytomegalovirus.Pediatrics · 2024Article
- Inconsistent Provider Testing Practices for Congenital Cytomegalovirus: Missed Diagnoses and Missed Opportunities.International journal of neonatal screening · 2022Article
- Missing diagnoses of congenital cytomegalovirus infection in electronic health records for infants with laboratory-confirmed infection.Current medical research and opinion · 2022Article
- Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy.Journal of the Pediatric Infectious Diseases Society · 2022Article
- Identification of congenital CMV cases in administrative databases and implications for monitoring prevalence, healthcare utilization, and costs.Current medical research and opinion · 2021Article
- Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies.Seminars in perinatology · 2021Review
- Congenital CMV-Coded Diagnosis Among American Indian and Alaska Native Infants in the United States, 2000-2017.Journal of immigrant and minority health · 2020Article
- Diagnosis and medical care for congenital cytomegalovirus infection: An observational study using claims data in Japan, 2010 to 2017.Medicine · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThe aim of this study was to assess the clinical characteristics and trends in valganciclovir use among infants diagnosed with congenital cytomegalovirus (CMV) disease in the United States.
methodsWe analyzed data from medical claims dated 2009-2015 from the Truven Health MarketScan
findingsIn the commercial and Medicaid databases, we identified 257 (2.5/10,000) and 445 (3.3/10,000) infants, respectively, diagnosed with congenital CMV disease, among whom 135 (53%) and 282 (63%) had ≥1 CMV-associated condition, 30 (12%) and 32 (7%) had hearing loss, and 41 (16%) and 78 (18%) had a claim for valganciclovir. Among infants with congenital CMV disease who had a claim for valganciclovir, 37 (90%) among commercially insured infants and 68 (87%) among Medicaid-insured infants had ≥1 CMV-associated condition and/or hearing loss. From 2009 to 2015, the percentages with a claim for valganciclovir increased from 0% to 29% among commercially insured infants and from 4% to 37% among Medicaid-insured infants (P < 0.0001). IMPLICATIONS: During 2009-2015, there was a strong upward trend in valganciclovir claims among insured infants who were diagnosed with congenital CMV disease, the majority of whom had CMV-associated conditions and/or hearing loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.